Page 16 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 16
Enfortumab vedotin
• Targets Nectin-4 • Received Breakthrough Therapy
o Which is expressed on many solid designation from the FDA in March
tumours, including urothelial 2018
carcinoma 1
• Consists of a monoclonal antibody • Pending Health Canada submission /
against Nectin-4 conjugated to a
microtubule-disrupting agent 1 approval
A biomarker test is not required
1. Challita-Eid PM et al. Cancer Res 2016;76:3003–13
